Climb Bio (CLYM) financial statements
Net income was -$60M.
Free cash flow was -$55M.
The diluted share count rose 3000% over the period (dilution).
Income statement
Fiscal years, from Climb Bio's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $9M | $23M | $26M | $15M | $14M | $47M |
| Selling, general and admin | $2M | $12M | $19M | $25M | $16M | $21M |
| Operating income | -$21M | -$36M | -$45M | -$40M | -$82M | -$68M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21M | -$47M | -$45M | -$35M | -$74M | -$60M |
| EPS (diluted) | -$10.49 | -$4.24 | -$1.72 | -$1.30 | -$1.53 | -$0.88 |
| Diluted shares | 2M | 12M | 26M | 27M | 48M | 68M |
Balance sheet
Fiscal years, from Climb Bio's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $20M | $161M | $124M | $107M | $151M | $161M |
| Total current assets | $22M | $148M | $134M | $110M | $155M | $106M |
| Property, plant and equipment | — | — | — | — | $199,000 | $288,000 |
| Total assets | $25M | $173M | $135M | $110M | $217M | $168M |
| Total current liabilities | $3M | $6M | $6M | $3M | $5M | $7M |
| Total liabilities | $3M | $6M | $6M | $3M | $5M | $7M |
| Shareholders' equity | -$25M | $167M | $129M | $108M | $212M | $160M |
| Net debt | -$20M | -$47M | -$44M | -$93M | -$87M | -$36M |
Cash flow
Fiscal years, from Climb Bio's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14M | -$36M | -$37M | -$21M | -$16M | -$54M |
| Capital spending | — | — | — | $0 | $0 | $186,000 |
| Free cash flow | — | — | — | -$21M | -$16M | -$55M |
| Stock-based compensation | $707,000 | $4M | $7M | $13M | $6M | $8M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CLYM.
Open CLYM in InvestinglyQuestions
How much free cash flow does Climb Bio generate?
-$55M in fiscal 2025 (operating cash flow minus capital spending).
From Climb Bio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.